![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Active Filter(s):
Details:
The Proceeds from the financing will be used to advance the Company’s lead program ProGly-Uricase into the clinic for the treatment of refractory gout and to broaden the GRObio pipeline.
Lead Product(s): Undisclosed
Therapeutic Area: Rheumatology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Atlas Venture
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing July 19, 2024
Details:
The proceeds will support development of the GRO platform, scale-up of bioprocess manufacturing, preclinical validation studies and IND-enabling studies for GRObio’s pipeline of unique non-standard amino acid protein therapeutics to treat autoimmune and metabolic diseases.
Lead Product(s): NSAA-protein Therapeutics
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Digitalis Ventures
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 03, 2021